This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Imagabalin
DrugBank Accession Number
DB12105
Background

Imagabalin has been investigated in Generalized Anxiety Disorder.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 173.256
Monoisotopic: 173.141578856
Chemical Formula
C9H19NO2
Synonyms
  • Imagabalin
External IDs
  • PD 0332334
  • PD-0332334
  • PF-00195889

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Imagabalin is combined with 1,2-Benzodiazepine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Imagabalin.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Imagabalin.
AclidiniumImagabalin may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imagabalin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Imagabalin.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Imagabalin.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Imagabalin.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Imagabalin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imagabalin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Imagabalin HydrochlorideMJ3F8ZA7Q1610300-00-0CFMZXQJDAJXNHS-WLYNEOFISA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Beta amino acids and derivatives
Alternative Parents
Medium-chain fatty acids / Branched fatty acids / Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Substituents
Aliphatic acyclic compound / Amine / Amino acid / Amino fatty acid / Beta amino acid or derivatives / Branched fatty acid / Carbonyl group / Carboxylic acid / Fatty acid / Fatty acyl
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
NDG6931B7H
CAS number
610300-07-7
InChI Key
JXEHXYFSIOYTAH-SFYZADRCSA-N
InChI
InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
IUPAC Name
(3S,5R)-3-amino-5-methyloctanoic acid
SMILES
CCC[C@@H](C)C[C@H](N)CC(O)=O

References

General References
Not Available
PubChem Compound
10236037
PubChem Substance
347828406
ChemSpider
8411525
ChEMBL
CHEMBL2103836
Wikipedia
Imagabalin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentGeneralized Anxiety Disorder1
3TerminatedTreatmentAnxiety Disorders1
3TerminatedTreatmentGeneralized Anxiety Disorder4
3WithdrawnTreatmentGeneralized Anxiety Disorder1
2CompletedTreatmentGeneralized Anxiety Disorder1
1CompletedNot AvailablePharmacokinetics / Renal Dialysis1
1CompletedDiagnosticGeneralized Anxiety Disorder1
1TerminatedNot AvailableGeneralized Anxiety Disorder2
1TerminatedNot AvailableImpaired Renal Function / Pharmacokinetics1
1WithdrawnNot AvailableGeneralized Anxiety Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.01 mg/mLALOGPS
logP-0.48ALOGPS
logP-0.61Chemaxon
logS-1.8ALOGPS
pKa (Strongest Acidic)4.53Chemaxon
pKa (Strongest Basic)10.54Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area63.32 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity48 m3·mol-1Chemaxon
Polarizability20.09 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:21 / Updated at February 21, 2021 18:53